卵泡抑素样蛋白1促进肺动脉内皮细胞增生、黏附与血管生成

doi:10.3969/j.issn.1006-7795.2020.01.016

首都医科大学学报 ›› 2020, Vol. 41 ›› Issue (1): 80-86.doi: 10.3969/j.issn.1006-7795.2020.01.016

卵泡抑素样蛋白1促进肺动脉内皮细胞增生、黏附与血管生成

沙宇惠¹, 高阳¹, 刘杰^1,2, 齐先梅^1,2, 韩璐璐¹, 王望^1,2

1. 首都医科大学基础医学院, 北京 100069;
2. 首都医科大学基础医学院生理学与病理生理学系, 北京 100069

收稿日期:2019-07-12 出版日期:2020-02-21 发布日期:2020-02-13
通讯作者: 王望 E-mail:wangwang.star@163.com
基金资助:
国家自然科学基金（31600939），北京市自然科学基金（7174280），北京市优秀人才培养资助项目（2015000020124G111），首都医科大学科研创新基金资助项目（XSKY2018014）。

FSTL1 promotes proliferation, adhesion and tube formation of pulmonary artery endothelial cells

Sha Yuhui¹, Gao Yang¹, Liu Jie^1,2, Qi Xianmei^1,2, Han Lulu¹, Wang Wang^1,2

1. School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China;
2. Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China

Received:2019-07-12 Online:2020-02-21 Published:2020-02-13
Supported by:
This study was supported by National Natural Science Foundation of China (31600939), Natural Science Foundation of Beijing (7174280), Beijing Talents Training Project (2015000020124G111), Innovation Foundation of Capital Medical University (XSKY2018014).

摘要/Abstract

摘要： 目的探究卵泡抑素样蛋白1（follistatin-like 1，FSTL1）对人肺动脉内皮细胞（human pulmonary artery endothelial cells，HPAECs）的影响，完善FSTL1在肺动脉高压（pulmonary hypertension，PH）中的作用。方法以人肺动脉内皮细胞为对象，使用qRT-PCR和Western blotting法测定低氧刺激下HPAECs中FSTL1的表达水平。通过给予外源性FSTL1蛋白或小干扰RNA，MTT法观察FSTL1对细胞增生活性的影响。分别借助纤连蛋白、Matrigel基质胶观察FSTL1对内皮细胞黏附与血管形成能力的影响。结果低氧刺激HPAECs 12 h和24 h后，FSTL1的mRNA及蛋白质的表达量均提高（P<0.01）。常氧下外源给予FSTL1，250 μg/L、500 μg/L组的细胞增生活性与对照组相比明显增高（P<0.01）；低氧条件下siRNA干扰组HPAECs增生活性与对照组相比明显降低（P<0.001）。常氧下外源给予250 μg/L的FSTL1刺激24 h后HPAECs黏附数量增多（P<0.001），生成血管总长度及新生血管数目均增加（P<0.001）。结论 FSTL1促进HPAECs增生、黏附与血管生成。

关键词: 肺动脉高压, 低氧, 卵泡抑素样蛋白1(FSTL1), 人肺动脉内皮细胞

Abstract: Objective To investigate the effect of follistatin-like 1(FSTL1) on human pulmonary artery endothelial cells (HPAECs) and to replenish the role of FSTL1 in pulmonary hypertension (PH). Methods The levels of FSTL1 in HPAECs were evaluated by qRT-PCR and Western blotting. Cellular viability was determined by MTT after giving exogenous recombinant human FSTL1 or small interfering RNA (siRNA). We also observed the effect of FSTL1 on adhesion and angiogenesis in HPAECs. Results Exposure to hypoxia upregulated the expression of FSTL1 mRNA and protein in HPAECs (P<0.01). The cellular viability of HPAECs stimulated by FSTL1 250 μg/L and 500 μg/L were higher than FSTL1 0 μg/L group under normoxia (P<0.01). SiRNA-mediated knockdown of FSTL1 attenuated hypoxia-induced proliferation of HPAECs compared with the negative control group (P<0.001). The amount of adherent cells stimulated with FSTL1 250 μg/L was increased under normoxia compared with that in the control group (P<0.001). The total length and the amount of tubes formed by HPAECs stimulated with FSTL1 250 μg/L were both increased under normoxia compared with the control group (P<0.001). Conclusions FSTL1 promotes proliferation, adhesion and tube formation of HPAECs.

Key words: pulmonary hypertension, hypoxia, follistatin-like 1(FSTL1), human pulmonary artery endothelial cells

中图分类号:

R363.2

沙宇惠, 高阳, 刘杰, 齐先梅, 韩璐璐, 王望. 卵泡抑素样蛋白1促进肺动脉内皮细胞增生、黏附与血管生成[J]. 首都医科大学学报, 2020, 41(1): 80-86.

Sha Yuhui, Gao Yang, Liu Jie, Qi Xianmei, Han Lulu, Wang Wang. FSTL1 promotes proliferation, adhesion and tube formation of pulmonary artery endothelial cells[J]. Journal of Capital Medical University, 2020, 41(1): 80-86.

参考文献

[1] Simonneau G, Montani D, Celermajer D S, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension[J]. Eur Respir J, 2019, 53(1):1801913.
[2] D'Alessandro A, EI Kasmi K C, Plecita-Hlavata L, et al. Hallmarks of pulmonary hypertension:mesenchymal and inflammatory cell metabolic reprogramming[J]. Antioxid Redox Signal, 2018, 28(3):230-250.
[3] Qiao F, Zou Z, Liu C, et al. ROCK2 mediates the proliferation of pulmonary arterialendothelial cells induced by hypoxia in the development of pulmonary arterial hypertension[J]. Exp Ther Med, 2016, 11(6):2567-2572.
[4] 唐琴,秦光梅.内皮细胞与低氧性肺动脉高压的发病机制[J].临床肺科杂志, 2015, 20(8):1512-1515.
[5] Tuder R M. Pulmonary vascular remodeling in pulmonary hypertension[J]. Cell Tissue Res, 2017, 367(3):643-649.
[6] Li C, Liu P, Song R, et al. Immune cells and autoantibodies in pulmonary arterial hypertension[J]. Acta Biochim Biophys Sin, 2017, 49(12):1047-1057.
[7] Nadeau V, Potus F, Boucherat O, et al. Dual ETA/ETB blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension[J]. Pulm Circ, 2018, 8(1):1-15.
[8] Chaly Y, Hostager B, Smith S, et al. Follistatin-like protein 1 and its role in inflammation and inflammatory diseases[J].Immunol Res, 2014, 59(1-3):266-272.
[9] Zhang W, Wang W, Liu J, et al. Follistatin-like 1 protects against hypoxia-inducedpulmonary hypertension in mice[J]. Sci Rep, 2017, 7:1-14.
[10] Yang Y, Mu T, Li T, et al. Effects of FSTL1 on the proliferation and motility of breast cancer cells and vascular endothelial cells[J]. J Thorac Cancer, 2017, 8(6):606-612.
[11] Mattiotti A, Prakash S, Barnett P, et al. Follistatin-like 1 in development and human diseases[J]. J Cell Mol Life Sci, 2018, 75(13):2339-2354.
[12] Simonneau G, Gatzoulis M A, Adatia I, et al. Updated clinical classification ofpulmonary hypertension[J]. Turk Kardiyol Dern Ars, 2014, 42(1):45-54.
[13] Hoeper M M, Ghofrani H A, Grunig E, et al. Pulmonary hypertension[J]. Dtsch Arztebl Int, 2017, 114(5):73-84.
[14] Fein D G, Zaidi A N, Sulica R. Pulmonary Hypertension Due to Common Respiratory Conditions:Classification, Evaluation and Management Strategies[J]. J Clin Med, 2016, 5(9):75.
[15] Andersen K H, Iversen M, Kjaergaard J, et al. Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease[J].Heart Lung Transplant, 2012, 31(4):373-380.
[16] Stenmark K R, Fagan K A, Frid M G. Hypoxia-induced pulmonary vascularremodeling:cellular and molecular mechanisms[J]. Circ Res, 2006, 99:675-691.
[17] Liu J, Wang W, Wang L et al. IL-33 initiates vascular remodelling in hypoxic pulmonary hypertension by up-regulating HIF-1α and VEGF expression in vascular endothelial cells[J]. EBioMedicine, 2018, 33:196-210.
[18] Wang L, Liu J, Wang W, et al. Targeting IL-17 attenuates hypoxia-induced pulmonary hypertension through downregulation of β-catenin[J]. Thorax, 2019, 74(6):564-578.
[19] 张红,胡晓霞,洛若愚,等.卵泡抑素样蛋白1与宫颈癌高危型HPV感染关联性研究[J].中华肿瘤防治杂志,2019,26(10):675-681.
[20] Chiou J, Su C Y, Jan Y H, et al. Decrease of FSTL1-BMP4-Smad signaling predicts poor prognosis in lung adenocarcinoma but not in squamous cell carcinoma[J]. J Sci Rep, 2017, 7(1):6830.
[21] Fang Y, Zhang S, Li X, et al. Follistatin like-1 aggravates silica-induced mouse lung injury[J].J Sci Rep, 2017, 7(1):399.
[22] Dong Y, Geng Y, Li L, et al. Blocking follistatin-like 1 attenuates bleomycin-induced pulmonary fibrosis in mice[J]. J Exp Med, 2015, 212(2):235-252.
[23] Shen H, Gui G, Li Y,et al. Follistatin-like 1 protects mesenchymal stem cells from hypoxic damage and enhances their therapeutic efficacy in a mouse myocardial infarction model[J]. Stem Cell Res Ther, 2019, 10(1):17.
[24] Gu C, Wang X, Long T,et al. FSTL1 interacts with VIM and promotes colorectal cancer metastasis via activating the focal adhesion signalling pathway[J]. Cell Death Dis, 2018, 9(6):654.
[25] Jin X, Nie E, Zhou X,et al. FSTL1 promotes glioma growth through the BMP4/Smad1/5/8 signaling pathway[J]. Cell Physiol Biochem, 2017, 44(4):1616-1628.
[26] Xi Y, Gong D W, Tian Z,et al. FSTL1 as a pontential mediator of exercise-induced cardiorotection in post-myocardial infarction rats[J]. Sci Rep, 2016, 6:32424.

卵泡抑素样蛋白1促进肺动脉内皮细胞增生、黏附与血管生成

FSTL1 promotes proliferation, adhesion and tube formation of pulmonary artery endothelial cells

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵文博, 任长虹, 李思颉, 马红蕊, 吉训明. 低氧与缺血适应防治缺血性脑卒中新技术体系的创研及推广应用——2020年度国家科学技术进步奖二等奖[J]. 首都医科大学学报, 2022, 43(1): 1-5.
[2]	李珺, 李硕硕, 彭志鑫, 廖亚金, 程金波, 袁增强. 小胶质细胞组蛋白去乙酰化酶3在低压低氧诱导的氧化应激中的作用[J]. 首都医科大学学报, 2022, 43(1): 91-98.
[3]	邓会, 王勇, 陈小兰, 秦崇, 潘磊. 不同时间低压低氧刺激对大鼠肺动脉压力及肺组织的影响[J]. 首都医科大学学报, 2021, 42(4): 596-600.
[4]	程姣姣, 阮祥燕, 杜娟, 谷牧青. 间充质干细胞对人冻融卵巢组织移植后低氧期保护作用的研究进展[J]. 首都医科大学学报, 2020, 41(4): 536-541.
[5]	范正阳, 谢江, 李菲, 王婧婷, 帕提古丽·依司拉木, 孙丹册. 睡眠重叠综合征患者发生肺动脉高压的相关因素调查[J]. 首都医科大学学报, 2020, 41(3): 482-487.
[6]	焦时宇, 于宝琪, 曲爱娟. 低氧诱导因子:氧稳态的砝码——2019年诺贝尔生理学或医学奖简介[J]. 首都医科大学学报, 2019, 40(5): 805-809.
[7]	齐先梅, 王蕾, 张瑞恒, 柳婷, 刘杰, 杨汀, 王军, 张知非, 王辰. MCC950在野百合碱诱导大鼠肺动脉高压模型中的治疗作用及其机制研究[J]. 首都医科大学学报, 2018, 39(6): 871-876.
[8]	高阳, 刘杰, 王蕾, 张炜, 刘亚飞, 齐先梅, 王望. 两种低氧性肺动脉高压小鼠模型的建立与比较[J]. 首都医科大学学报, 2018, 39(4): 563-568.
[9]	杨一帆, 秦一, 徐唯哲, 徐平湘, 薛明. 吡硫醇在低氧与常氧环境下大鼠体内的药代动力学研究[J]. 首都医科大学学报, 2017, 38(2): 232-237.
[10]	房亚兰, 李森, 赵咏梅, 闫峰, 尹洁, 罗玉敏, 刘克建. 螯合锌离子对局灶性脑缺血再灌注大鼠半暗带区低氧诱导因子-1α表达的影响[J]. 首都医科大学学报, 2016, 37(5): 626-630.
[11]	杨毅, 刘楠, 候晓彤, 孙立忠, 王红, 金祺. HFNC与NPPV对于心外科术后低氧血症患者的疗效研究[J]. 首都医科大学学报, 2016, 37(5): 664-671.
[12]	张巧云, 李思颉, 牛敬忠, 邵国, 吉训明, 张颜波. 低氧预适应对急性脑梗死小鼠血清TNF-α、IL-1β和IL-6炎性反应因子的影响[J]. 首都医科大学学报, 2016, 37(1): 89-92.
[13]	柳婷, 刘亚飞, 王望, 柴三葆, 刘杰, 王军. 格列本脲对野百合碱诱导的大鼠肺动脉高压的影响及其可能机制[J]. 首都医科大学学报, 2015, 36(5): 723-728.
[14]	黄莹, 张建, 陈兵, 郭连瑞, 李建新, 张淑文. 低氧有助于小鼠骨髓源间充质干细胞的定向分化[J]. 首都医科大学学报, 2015, 36(1): 18-22.
[15]	国桓, 王望, 孙然, 刘杰, 王军. 低氧对大鼠不同级别肺动脉平滑肌细胞功能的影响[J]. 首都医科大学学报, 2014, 35(2): 231-236.